Investor Relations
NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. Please click here for more on our clinical trial status.
NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.
Stock Data
NRX Pharmaceuticals Inc. (NRXP)
NASDAQNRXP
NASDAQNRXP
Detailed Quote
NASDAQNRXP
1dy
1mo
6mo
1yr
5yr
Recent News
Bottom Global Links (above footer)